Medical Diagnosis has advanced monumentally in recent years. Regardless, prior detection of Bone Metastasis can be complicated, and the detection of its presence often means that the patient has reached an advanced disease stage and has only a little time left with a few likely treatment options.
The foremost goal of these treatment options is not to overcome the condition but rather to relieve the associated pain, prevent further bone complications, and sustain a good quality of life. Upon diagnosis of the first metastatic bone cancer, the life expectancy is often around 6–48 months.
What Is Bone Metastasis?
Bone Metastasis is most commonly observed in patients suffering from lung, prostate, and breast cancer. It occurs in advanced cancer patients when cancerous cells from the primary tumor move to the bone.
Its symptoms include weakness in legs or arms, broken bones, bone pain, bowel and urinary incontinence, and hypercalcemia (a condition where high levels of calcium are seen in the blood), which lead to nausea, constipation, vomiting, and confusion.
Since this condition has adverse clinical consequences, a prompt and precise diagnosis is thus necessary. The diagnosis usually includes looking for symptoms, signs, and imaging. Laboratory tests include Plain X-ray, Computed Tomography (CT), and Radionuclide Bone Scintigraphy that can be used as the imaging methods for detecting Bone Metastasis.
What Are The Treatment For Bone Metastasis
According to the reports, breast cancer has the highest prevalent cases of Bone Metastasis, with around 121,603 reported cases in 2020, within the metastatic group in the United States, followed by lung cancer, prostate cancer, and other solid tumors.
Further analysis shows that the number of cases of Bone Metastasis established on tumor type could climb by 2030 due to the increasing incidence of cancer globally, which could make a positive shift in the Bone Metastasis market.
A study of the Bone Metastasis Treatment Market describes the current therapies, the key companies, and the emerging pipeline in further detail. The study also indicates the progression of developmental stages and the survival rate of Bone metastasis as observed in many patients over the years.
Bone Metastasis is hardly ever cured, and the only way of treatment is through disease control, performed using systemic anticancer therapies built on multidisciplinary supportive care.
This care includes using denosumab or bisphosphonates (a bone-targeting agent) to prevent skeletal morbidity and inhibit tumor-related osteolysis. Appropriate local treatments such as specialist palliative care, radiation therapy, orthopedic surgery are further used to reduce the impact of metastatic bone disease on bodily functioning.
The Future
It is necessary to develop novel strategies that improve the patient’s quality of life by averting skeletal disease and palliating established skeletal events. In addition, more studies are vital for understanding the interaction between the tumor cell and bone microenvironment so that effective new therapeutic interventions can be developed.
The entry of important pharmaceutical companies pioneering novel effective therapies, the discovery of new biomarkers for diagnosis, and R&D, shall propel the Bone Metastasis market landscape and treatment frame. With growing awareness of Bone Metastasis among people, the complete Bone Metastasis treatment landscape could change significantly in the coming years.
